We developed a first-in-class GADD45B/MKK7 inhibitor, DTP3, which selectively kills MM cells via MKK7/JNK-driven apoptosis and is not toxic to normal cells. The gene discussed is MAP2K7; the disease is Miyoshi myopathy.